This week’s trend of A-share and Hong Kong stock innovative drug sectors. In the fourth week of January 2022, a total of two stocks in mainland and Hong Kong innovative drug sectors rose and 45 stocks fell. Among them, the top two gainers are Maibo pharmaceutical-b (+ 7.78%) and Bio-Thera Solutions Ltd(688177) -u (+ 1.37%). The top three declines were tengshengbo medicine-b (- 26.10%), Xinda Biology (- 26.44%), Deqi medicine-b (- 26.84%). This week, the A-share innovative drug sector fell 9.69%, underperforming the CSI 300 index by 4.51pp, and biomedicine fell 6.39%. Over the past six months, A-share innovative drugs have fallen 17.32%, underperforming the CSI 300 index by 4.75pp, and biomedicine has fallen 37.12%. This week, the innovative drug sector of Hong Kong stocks fell by 12.39%, underperforming the Hang Seng Index by 5.67pp, and Hang Seng healthcare fell by 14.95%. Over the past six months, innovative drugs in Hong Kong stocks have fallen by 19.36%, underperforming the Hang Seng Index by 8.85pp, and Hang Seng health care has fallen by 42.38%.
Progress of key innovative drugs in China
This week, two drugs in China were approved by nmpa for listing, one ind was approved by nmpa, one ind was approved by FDA and one NDA was accepted by nmpa. Nmpa approved North China Pharmaceutical Company.Ltd(600812) omativumab for the treatment of rabies. Neogene’s riblozer has been approved by nmpa to treat adults who need regular infusion of red blood cells (RBC) β- Patients with thalassemia.
Progress of overseas key innovative drugs
In January, 6 new drugs were approved by FDA and 2 new drugs were approved this week. The new daptomycin dosage form / new manufacturer of Baxter hlthcare Corp was approved for marketing on January 25. Aftep for melanoma was approved on January 25th by hltep.
This week’s small topic – development progress of protac drugs
Protac shows potential in overcoming drug resistance and targeting non drug targets, and has become a very popular direction in new drug research and development. A total of 19 protac drugs in the world are in clinical or declared clinical stage, 3 are in phase I / II clinical stage and 13 are in phase I clinical stage. Representative companies of protac technology include arvinas, C4 therapeutics, kymera therapeutics, etc. Arvinas two protac drugs arv-110 and arv-471, which are in the first stage of clinical treatment, have shown positive efficacy data and have a promising prospect.
Three Chinese companies have arranged protac projects, namely, development of pharmaceutical industry (target AR), Haisco Pharmaceutical Group Co.Ltd(002653) (target Btk) and Baiji Shenzhou (target Btk), which are in phase I clinical stage.
Progress of global key innovative drug transactions this week
There were 9 key transactions in the world this week, and 3 key transactions with disclosed amount, involving companies including aurealis therapeutics and xbiome, Walvax Biotechnology Co.Ltd(300142) and blue magpie biology, Capricorn therapeutics and Nippon shinyaku.
Risk warning: drug price reduction risk; The implementation progress of medical reform policy is lower than the expected risk; Risk of R & D failure.
